AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02202603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo
Study NCT02202603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo
Study NCT01859429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
Study NCT04589494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride
Description: tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
Study NCT02680301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone CREAM
Description: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
Study NCT02680301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone OINTMENT
Description: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
Study NCT03953560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dyspnea grade ≥ II according NYHA-WHO
Description: Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis
Study NCT03881163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
Study NCT00923091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
Study NCT02492711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: 15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
Study NCT02492711 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
Study NCT01850602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study NCT01850602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Study NCT03838783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: 50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
Study NCT02184351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxanes's clotrimazole troches
Study NCT02184351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycelex® troches
Study NCT03477929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate
Description: multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Study NCT03477929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Study NCT02452463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02452463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02452463 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00796562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
Study NCT00796562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patient will receive Cy by IV once a day for 2 days.
Study NCT00796562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Patients will receive TBI once a day for 4 days.
Study NCT02355730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
Study NCT01409499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: palliative hepatectomy followed by sorafenib
Study NCT01409499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter hepatic arterial chemoembolization
Description: TACE followed by sorafenib
Study NCT01409499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib monotherapy, 400mg Bid, continuously
Study NCT03006835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT03006835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02350998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Study NCT06384703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Taking blood for kit study
Description: Taking blood for kit study (Elisa kit)
Study NCT01034215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Envision the Rhythms of Life Program
Description: Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
Study NCT04579419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Botulinum Toxin diluted in Sodium Bicarbonate
Study NCT04579419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9 NaCl
Study NCT01034215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Envision the Rhythms of Life Program/Distance
Description: Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
Study NCT04848090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neonate WGS Testing
Description: Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling.
Study NCT02302326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose: metformin (1700 mg / day) for 12 weeks
Study NCT02302326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + folic acid
Description: Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
Study NCT02065804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: injection, once, 5 min
Study NCT01252303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrisystem
Description: Nutrisystem meal replacements for 12 weeks
Study NCT02327559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind in Labor (MIL): Working with Pain in Childbirth
Description: The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
Study NCT02327559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis).
Study NCT02022150 — intervention group
Intervention type: BEHAVIORAL
Intervention: Body composition in paracentesis
Description: Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
Study NCT00730691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study NCT00730691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching capsules
Study NCT00730691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets
Study NCT00730691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Overencapsulated duloxetine capsules
Study NCT02716311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Study NCT02716311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT02716311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00052221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Study NCT00052221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01488435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk
Description: Powdered whole cow's milk
Study NCT01488435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-On Formula
Description: Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
Study NCT03580915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Literacy Program
Description: The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
Study NCT03580915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Management Services
Description: The control group will receive the usual housing services without additional intervention.
Study NCT03580915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Management Services
Description: The control group will receive the usual housing services without additional intervention.
Study NCT03214588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 tablets
Study NCT03214588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-831 Placebo
Description: TAK-831 placebo matching tablets
Study NCT01958294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MICHI Neuroprotection System
Study NCT02065804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: injection, once, 5 min
Study NCT03852693 — intervention group
Intervention type: OTHER
Intervention: Histopathological review
Description: Histopathological review
Study NCT01252303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem
Description: Nutrisystem meal replacements for 12 weeks
Study NCT01634178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration
Study NCT02570958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
Study NCT00864396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: 30mg of Lansoprazole twice daily (or placebo)for eight weeks.
Study NCT01837914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expansion
Study NCT01837914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion
Study NCT01837914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy
Study NCT01837914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Study NCT03158727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cx611
Description: Two intravenous infusions, one on day 1 and another one on day 3.
Study NCT03158727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intravenous infusions, one on day 1 and another one on day 3.
Study NCT01862601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JetTouch Needle-free injection system
Description: Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
Study NCT02153203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent-Teach-Reinforce Model
Description: Implementation of the model once to twice per week over a period of 8 weeks
Study NCT02153203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Parent Training Session
Description: One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
Study NCT01358071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT01358071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Study NCT01358071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Study NCT01358071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study NCT01358071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study NCT04025476 — intervention group
Intervention type: DRUG
Intervention: Steroids
Description: IV and oral steroids
Study NCT01680237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
Study NCT01680237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in-vivo
Description: Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
Study NCT01844479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diabetic foot orthotic
Description: The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
Study NCT01844479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard innersole